Management of Retinal Pigment Epithelium Tear During Anti–vascular Endothelial Growth Factor Therapy

Mitchell, Paul; Rodriguez, Francisco J.; Joussen, Antonia M.; Koh, Adrian; Eter, Nicole; Wong, David T.; Korobelnik, Jean‐François; Okada, Annabelle A.

doi:10.1097/iae.0000000000003083

Cited by 10 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The safety profile of IVT-AFL over the 2-year study was consistent with that of prior observational studies [9][10][11][12][13] and no unexpected safety signals were identified. The incidence of retinal pigment epithelial tear during anti-VEGF therapy in PERSEUS-IT is similar to that reported for untreated cases of nAMD; there is no clear evidence of differing risk according to anti-VEGF agent use or type [19].…”

Section: Discussionsupporting

confidence: 66%

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration

Nicolò

Ciucci

Nardi

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose PERSEUS-IT (NCT02289924) was a prospective, observational, 2-year study evaluating the effectiveness and treatment patterns of intravitreal aflibercept (IVT-AFL) in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice in Italy. Methods Treatment-naïve patients with nAMD receiving IVT-AFL per routine clinical practice were enrolled. The primary endpoint was mean change in visual acuity (VA; decimals) from baseline to month (M) 12 and M24. Outcomes were evaluated for the overall study population and independently for the 2 treatment cohorts: regular (3 initial monthly doses, ≥ 7 injections by M12, and ≥ 4 injections between M12 and M24) and irregular (any other pattern). Results Of 813 patients enrolled, 709 were included in the full analysis set (FAS); VA assessments were available for 342 patients at M12 (FAS1Y, 140 regular and 202 irregular) and 233 patients at M24 (FAS2Y, 37 regular and 196 irregular). In the overall FAS, the mean ± SD change in VA from baseline to M12 and M24 was + 0.09 ± 0.24 and + 0.02 ± 0.25 decimals, and there was a statistically significant difference between the regular and irregular cohorts in both FAS1Y (p = 0.0034) and FAS2Y (p = 0.0222). Ocular treatment-emergent adverse events were reported in 4.1% (n = 33/810 [safety set]) of patients. Conclusion In PERSEUS-IT, clinically relevant functional and anatomic improvements were observed within the first 12 months of IVT-AFL treatment in routine clinical practice in Italy in patients with treatment-naïve nAMD. These gains were generally maintained across the 2-year study. The safety profile of IVT-AFL was consistent with prior studies. Trial registration number ClinicalTrials.gov Identifier: NCT02289924. Date of registration November 13, 2014.

show abstract

Section: Discussionsupporting

confidence: 66%

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration

Nicolò

Ciucci

Nardi

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Tears of the RPE have been well-documented during both the natural history and treatment of wAMD, [89,90] occurring in approximately 10-12% of patients with wAMD. [91] They traditionally occur in type 1 MNV, with a large, vascularized, and often peaked PED, [92] and contracture of the MNV is thought to produce tensile forces on RPE attachment junction, eventually resulting in tearing of the RPE. As this is a structural complication of the RPE, SW-AF is particularly suited for imaging this feature.…”

Section: Age-related Macular Degeneration (Amd)mentioning

confidence: 99%

Fundus Autofluorescence and Clinical Applications

Pole

Ameri

2021

JOVR

View full text Add to dashboard Cite

Fundus autofluorescence (FAF) has allowed in vivo mapping of retinal metabolic derangements and structural changes not possible with conventional color imaging. Incident light is absorbed by molecules in the fundus, which are excited and in turn emit photons of specific wavelengths that are captured and processed by a sensor to create a metabolic map of the fundus. Studies on the growing number of FAF platforms has shown each may be suited to certain clinical scenarios. Scanning laser ophthalmoscopes, fundus cameras, and modifications of these each have benefits and drawbacks that must be considered before and after imaging to properly interpret the images. Emerging clinical evidence has demonstrated the usefulness of FAF in diagnosis and management of an increasing number of chorioretinal conditions, such as agerelated macular degeneration, central serous chorioretinopathy, retinal drug toxicities, and inherited retinal degenerations such as retinitis pigmentosa and Stargardt disease. This article reviews commercial imaging platforms, imaging techniques, and clinical applications of FAF.

show abstract

“…(J Glaucoma 2023;32:e60-e62) R etinal pigment epithelium (RPE) tear is a well-known complication of retinal pigment epithelial detachment (PED), particularly neovascularized PED in the context of age-related macular degeneration treated by intravitreal injections of anti-vascular endothelial growth factor drugs. 1 RPE tears have been described after intravitreal injections of steroids as well. It can also be a complication of laser treatments, especially photocoagulation and dynamic phototherapy.…”

mentioning

confidence: 99%

Retinal Pigment Epithelium Tear After Nonpenetrating Deep Sclerectomy

Cayzac

Sagnard

Valero

et al. 2023

Journal of Glaucoma

View full text Add to dashboard Cite

Retinal pigment epithelium (RPE) tear is a common complication in the context of neovascular age-related macular degeneration treated by intravitreal injections of antivascular endothelial growth factor drugs. There are some reports of such complications after trabeculectomy but none after nonpenetrating deep sclerectomy (NPDS). A 57-year-old man presented to our hospital with uncontrolled advanced glaucoma of his left eye. NPDS with adjunctive use of mitomycin C was performed with no intraoperative complication. On the seventh postoperative day clinical examination and multimodal imaging revealed a macular RPE tear in the operated eye. Subretinal fluid induced by the tear resolved within 2 months with an increase in intraocular pressure. To the best of our knowledge, this article discusses the first reported case of RPE tear occurring just after NPDS.

show abstract

Management of Retinal Pigment Epithelium Tear During Anti–vascular Endothelial Growth Factor Therapy

Cited by 10 publications

References 39 publications

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration

Fundus Autofluorescence and Clinical Applications

Retinal Pigment Epithelium Tear After Nonpenetrating Deep Sclerectomy

Contact Info

Product

Resources

About